CDXS - Codexis, Inc. Company Cash on Hand

Brandmark of codexis.com (CDXS)

Codexis, Inc. (CDXS) maintains a volume of highly liquid cash that demonstrates financial resilience, with the 0.07 level reflecting the current amount. The business is susceptible to the influence of global trade conflicts and logistical disruptions. Internal developments by pharma behemoths and the risk of synthetic production create significant pressure. However, the deep integration of unique enzymes into FDA protocols guarantees exceptional loyalty from the largest clients.

Company Liquid Assets: Codexis, Inc. (CDXS) for 07/04/2022 - 11/21/2026

Codexis, Inc. (CDXS) - metric breakdowns and financial figures

- stock quotes and analyst forecast:
- market capitalization statistics:
Comprehensive company analysis:Codexis, Inc.
Signature product of Codexis Bio

For Codexis, Inc. (CDXS), the volume of liquid assets directly determines the ability to sustain R&D during periods of irregular contract payments. This indicator aggregates available cash and equivalents, reflecting the business's actual financial autonomy. By analyzing the cash balance chart, an investor can see the market consensus regarding the issuer's solvency. A stable level of reserves minimizes the company's reliance on external borrowing when financing new developments.

Competitors of Codexis, Inc.

Company Cash Volume TEM|QGEN - Company Cash Reserve|ionispharma.com - Company Cash on Hand|Company Cash Balance RGEN|Avidity Corp - Company Cash Volume|CRISPR Therapeutics Corp - Company Total Cash Amount|GeneDx Holdings (WGS) - Company Cash Funds|Ultragenyx Pharmaceutical (RARE) - Company Cash Volume|Company Cash on Hand BEAM|Sarepta (SRPT) - Company Liquid Assets|Company Cash Funds Twist Bioscience Corp (TWST)|10x - Company Cash and Cash Equivalents|Company Cash Volume NTLA (intelliatx.com)|Company Total Cash Amount STOK (stoketherapeutics.com)|BioLife Solutions Inc - Company Cash Volume|WVE (Wave Life Sciences Ltd) - Company Cash and Cash Equivalents|Maze Therapeutics Corp (MAZE) - Company Cash Funds|Company Cash and Cash Equivalents SION|PRME (Prime Medicine Inc) - Company Cash Volume|Taysha Gene Therapies (TSHA) - Company Liquid Assets|Company Cash on Hand QURE (uniqure.com)|Company Total Cash Amount MGTX|Company Cash Volume RGNX (regenxbio.com)|SLDB: Company Cash and Cash Equivalents|ocugen.com - Company Cash Volume|PACB - Company Cash Volume|BNTC: Company Cash Volume|Company Cash and Cash Equivalents DSGN|Company Cash Funds Rocket Pharmaceuticals|Company Cash on Hand 4DMT (FDMT)|Company Cash Volume LXEO|Company Liquid Assets Korro Bio Inc.|Company Cash Volume EDIT (Editas Medicine Inc)|SLN: Company Cash and Cash Equivalents|PRQR - Company Cash Funds|Company Cash Position Sangamo (SGMO)|NAUT (Nautilus Bio) - Company Cash on Hand|MGX - Company Liquid Assets|DTIL (Precision BioSciences Inc.) - Company Cash Volume|generationbio.com (GBIO) - Company Liquid Assets|Company Cash Funds Boundless Bio Inc (BOLD)|Company Cash Volume Exicure Inc. (XCUR)|Company Cash Funds imunon.com IMNN|Company Cash Volume Phio Pharmaceuticals PHIO|Mustang Bio Inc - Company Cash Volume|Company Cash Reserve transcodetherapeutics.com|BNGO: Company Cash Volume|Company Cash and Cash Equivalents APDN|BLUE (bluebirdbio.com) - Company Cash Volume|Company Cash Reserve ImmunoPrecise Antibodies IPA|Company Cash on Hand OMGA (omegatherapeutics.com)|Company Cash Volume Singular Genomics Systems, Inc. (OMIC)|Company Cash Volume RGLS (Regulus Therapeutics, Inc.)|Company Cash Volume Syros SYRS|Telesis Bio, Inc. - Company Cash Volume|TRACON Pharmaceuticals (TCON) - Company Cash on Hand|UBX: Company Cash Volume